Epix Delaware, Inc.

Vidac Pharma Ltd.

Epix Pharmaceuticals, Inc.

Microdose Therapeutx, Inc.

Other

Nanotherapeutics, Inc.

Clevexel Pharma

Galenea Corp.

Vidac Pharama Ltd.

Dynamix Pharmaceuticals Ltd.

Predix Pharmaceuticals Holdings, Inc.

Trovis Pharmaceuticals, LLC

Oren Becker

Yael Marantz

Sharon Shacham

Silvia Noiman

Dale S Dhanoa

Srinivasa Rao Cheruku

Dongli Chen

Boaz Inbal

Mercedes Lobera

Shay Bar-Haim

Alexander Heifetz

Anurag Sharadendu

Pradyumna Mohanty

Vered Behar

Ashis K Saha

Laurence Wu

Pini Orbach

Merav Fichman

Nili Schutz

Dilara McCauley

Xiang Y Yu

Reut Yosef Hamo

Jian Lin

Paul Salama

Zhaoda Zhang

Raphael Nudelman

Eyal Dor-On

A Sekar Reddy

Rosa Melendez

Vincent Jacques

Venkitasamy Kesavan

Hanoch Senderowitz

Sima Mirilashvili

Avihai Yacovan

Efrat Ben-Zeev

Alina Shitrit

Michael Xie

Robert Christian Penland

Kimberley Gannon

Sharon Shachem

Victor J Cee

Brian Alan Lanman

Jennifer Elizabeth Golden

Roland W Burli

Susana C Neira

Gali Golan

Alex Aizikovich

Laurence I Wu

Rosa E Mele'ndez

Osnat Kashtan

Sekar A Reddy

Tzofit Kehat

Rachel Ozeri

Alexander Konson

Sharon Gazal

Itai Bloch

Sekar Reddy Alla

Hadas Tamar Pahima

Daniel Sherman

Robert C Penland

Susana Neira

Roland Burli

Dilara Mccaulay

Rosa E Melendez

The present invention relates to novel piperazine derivatives, methods for their preparation, pharmaceutical compositions including such compounds, and methods of using these compounds and compositions, especially for targeted therapy treatment of hyperproliferative disorders, including benign hyperproliferative disorders, cancer and pre-cancer conditions.

Piperazine derivatives, pharmaceutical compositions and methods of use thereof

The present invention provides methods of use of hexokinase 2 (HK2)/mitochondria-detaching compounds, including jasmonate derivatives and piperazine derivatives and pharmaceutical compositions including such compounds for inducing immune responses in a subject, including potentiating the immune response to hyperproliferative disorders such as cancer and potentiating the immune response to infectious diseases.

Use of hexokinase 2/mitochondria-detaching compounds for activating immune responses

This invention relates to methods for preparation of jasmonate compounds via a salt of jasmonic acid.

Methods for preparation of jasmonate compounds

The present invention provides methods of use of hexokinase 2 (HK2)/mitochondria-detaching compounds, including jasmonate derivatives and piperazine derivatives and pharmaceutical compositions including such compounds for treating, inhibiting, or suppressing a hexokinase-2 (HK2)-expressing cancer.

Use of hexokinase 2/mitochondria-detaching compounds for treating hexokinase-2 (HK2)-expressing cancers

Provided are adenosine analog compounds such as that act as P2Y receptors, e.g., the P2Yreceptor, including pharmaceutical compositions; and uses thereof to treat or prevent diseases associated with that receptor, e.g., disorders relating to mucus secretion, such as cystic fibrosis, chronic obstructive pulmonary disorder (COPD), asthma, constipation, chronic idiopathic constipation, dry mouth (xerostomia), gum disease, and gastrointestinal problems caused by radiation and chemotherapy for cancer.

Adenosine analogs and their use

The invention relates to compounds and methods for modulating one or more components of a kinase signaling cascade.

Compositions and methods for modulating a kinase

The invention relates to sulfonamide compounds and methods for activating PKM2. The compounds and methods are useful in treating or preventing a disease or disorder selected from cancer, cell proliferative disorder, inflammatory disorder, metabolic disorder, and immune system disorder.

Sulfonamides for the modulation of PKM2

The invention relates to 5-HTreceptor antagonists. Novel arylamine compounds and use of these compounds and their pharmaceutical compositions, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with serotonin action, such as in treating obesity, and obesity-related disorders, e.g., cardiovascular disease, digestive disease, respiratory disease, cancer and type II diabetes; and psychological disorders such as schizophrenia, are disclosed.

Substituted arylamine compounds and methods of treatment

Provided are adenosine analog compounds of the general formula that act as P2Y receptors, e.g., the P2Yreceptor, including pharmaceutical compositions; and uses thereof to treat or prevent diseases associated with that receptor, e.g., disorders relating to mucus secretion, such as cystic fibrosis, chronic obstructive pulmonary disorder (COPD), asthma, constipation, chronic idiopathic constipation, dry mouth (xerostomia), gum disease, and gastrointestinal problems caused by radiation and chemotherapy for cancer. 

The invention relates to 5-HT receptor agonists and partial agonists. Novel thienopyridinone compounds represented by Formula I, and synthesis and uses thereof for treating diseases mediated directly or indirectly by 5-HT receptors, are disclosed. Such conditions include Alzheimer's disease, cognition disorders, irritable bowel syndrome, nausea, emesis, vomiting, prokinesia, gastroesophageal reflux disease, nonulcer dyspepsia, depression, anxiety, urinary incontinence, migraine, arrhythmia, atrial fibrillation, ischemic stroke, gastritis, gastric emptying disorders, feeding disorders, gastrointestinal disorders, constipation, erectile dysfunction, and respiratory depression. Methods of preparation and novel intermediates and pharmaceutical salts thereof are also included.

Thienopyridinone compounds and methods of treatment

The present invention relates to compounds of the general formula (I) that have activity as S1P receptor modulating agents and the use of such compounds to treat diseases associated with inappropriate S1P receptor activity. The compounds may be used as immunomodulators, e.g., for treating or preventing diseases such as autoimmune and related immune disorders including systemic lupus erythematosus, inflammatory bowel diseases such as Crohn's disease and ulcerative colitis, type I diabetes, uveitis, psoriasis, myasthenia gravis, rheumatoid arthritis, non-glomerular nephrosis, hepatitis, Beh&#xe7;et's disease, glomerulonephritis, chronic thrombocytopenic purpura, hemolytic anemia, hepatitis and Wegner's granuloma; and for treating other conditions.

S1P receptor modulating compounds and use thereof

Growing community of inventors

Mevaseret Zion, Israel

Oren Becker